

Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019

<https://marketpublishers.com/r/MB8F4929A8A8EN.html>

Date: December 2019

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: MB8F4929A8A8EN

Abstracts

Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019

SUMMARY

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019, outlays comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor (GIF) is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells (DC) and T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF- α , nitric oxide and cyclooxygenase 2 (COX-2). MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to release MIF into the blood stream. The circulating MIF binds to CD74 on other immune

cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoid. The molecules developed by companies in Preclinical and Discovery stages are 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Respiratory, Dermatology and Infectious Disease which include indications Rheumatoid Arthritis, Glomerulonephritis, Inflammatory Bowel Disease, Multiple Sclerosis, Pulmonary Arterial Hypertension, Type 1 Diabetes (Juvenile Diabetes), Alzheimer's Disease, Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Crohn's Disease (Regional Enteritis), Idiopathic Pulmonary Fibrosis, Inflammation, Malaria, Myocardial Infarction, Obesity, Prostate Cancer, Psoriasis, Systemic Lupus Erythematosus, Type 2 Diabetes and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)

The report reviews Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Overview

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Companies Involved in Therapeutics Development

Apaxen

GlaxoSmithKline Plc

Ibex Biosciences LLC

Innovimmune Biotherapeutics Inc

L2 Diagnostics LLC

Mifcare

MIFCOR Inc

Takeda Pharmaceutical Co Ltd

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Drug Profiles

BaxB-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxG-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-88 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

malaria vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MFC-1040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MFC-2040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIF-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibits MIF for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit MIF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MIF for Autoimmune Disorders and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MIF for Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MIF for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Dormant Products

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Discontinued Products

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Product Development Milestones

Featured News & Press Releases

Jul 13, 2018: Yale researchers identify target for novel malaria vaccine

Jan 10, 2017: Abzyme receives Milestone Payment from Ibex for Anti-cancer VHH Antibodies

Sep 09, 2016: Mifcare Announces Positive Preclinical Efficacy Data for MFC1040 in Sugen/Chronic Hypoxia Model of Severe Pulmonary Arterial Hypertension

Jul 15, 2016: Mifcare Announces Positive Preclinical Results with MFC1040 in Pulmonary Arterial Hypertension

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Apaxen, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Ibex Biosciences LLC, H2 2019
Pipeline by Innovimmune Biotherapeutics Inc, H2 2019
Pipeline by L2 Diagnostics LLC, H2 2019
Pipeline by Mifcare, H2 2019
Pipeline by MIFCOR Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Apaxen

GlaxoSmithKline Plc

Ibex Biosciences LLC

Innovimmune Biotherapeutics Inc

L2 Diagnostics LLC

Mifcare

MIFCOR Inc

Takeda Pharmaceutical Co Ltd

I would like to order

Product name: Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/MB8F4929A8A8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MB8F4929A8A8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970